Skip to content

Psychiatry Research

ISSN 1872-7123, 0165-1781

160 papers in the library · 1,451 citations · publishing 1984-2026

Papers

Sort Most recent Most cited

Adverse reactions to psychedelics in naturalistic settings are associated with current psychopathology and well-being: A correlational study

Psychiatry Research October 1, 2026 Jaime Rojas-Hernández, Lucas F Borkel, Ángelo Santana Del Pino et al.

This study examines acute and delayed adverse reactions reported in naturalistic psychedelic use, focusing on their associations with substance-use patterns, contextual variables, and user motivations. Using an online survey incorporating the Psychedelic Use Scale, data were collected from a large naturalistic sample (N=1022) to analyze patterns of self-reported adverse reactions. Acute adverse...

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.

Psychiatry Research September 14, 2026 Kelei Xiao, Yealin Woo, Christine E. Dri et al.

Cognitive impairment is a core feature of major depressive disorder (MDD) and bipolar disorder (BD). Most conventional antidepressants do not have direct and clinically relevant procognitive effects. Ketamine and esketamine are effective in treating treatment-resistant depression (TRD). Herein, this systematic review aims to evaluate the effects of both pharmacotherapeutics on cognitive...

Subjective experiences of catatonia in acute psychiatric inpatients: An exploratory study.

Psychiatry Research August 11, 2026 Levente Csihi, Hunor Girasek, Rozália Takács et al.

The subjective experience of patients during catatonic episodes is a relatively neglected area of research. The aims of this study were to contribute empirical data to the literature by assessing catatonic patients' subjective experiences and to explore how patients' subjective experiences vary according to their underlying medical and psychiatric conditions. All 2,281 patients admitted to an...

Faster and greater antidepressant response to intravenous ketamine in bipolar compared with unipolar treatment-resistant depression: Diagnostic and sex-related findings from a naturalistic study.

Psychiatry Research August 1, 2026 Pietro Carmellini, Andrea Fagiolini, Mario Pinzi et al.

Intravenous ketamine has emerged as a rapid-acting antidepressant intervention that has shown promising effects in patients with treatment-resistant depression, although evidence remains heterogeneous and less well established across diagnostic subtypes. Nevertheless, real-world data comparing diagnostic subtypes and sex-related differences remain limited. This observational study examined the...

Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.

Psychiatry Research August 1, 2026 C. Bharat, Xin-Tong Huang, G. Campbell et al.

BACKGROUND Interest in cannabinoids for mental and substance use disorders is increasing. We examined experimental and observational evidence for treating these disorders and their symptoms. METHODS Systematic review and meta-analysis (PROSPERO CRD42023467536). We searched CENTRAL, MEDLINE, Embase and PsycINFO to May 2025 for studies of cannabinoids in adults (≥18 years) with ADHD, anxiety,...

Psychedelics as a potential treatment for borderline personality disorder: A narrative review.

Psychiatry Research July 1, 2026 Erin Artna, Guneet Sandhu, Noah Chisamore et al. 1 citation

Borderline personality disorder (BPD) is a serious mental illness with high rates of morbidity and stigma; however, successful remission is frequently limited by a paucity of accessible treatment options. In an era of growing interest in psychedelics as novel psychiatric treatment modalities, patients with BPD are often excluded from research due to perceived safety risks, particularly...

Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.

Psychiatry Research July 1, 2026 Yao Xiao, Ping Xie, Danlei Li et al.

Pharmacological treatment for postpartum depression (PPD) have mainly involved conventional antidepressants, RCTs have also evaluated rapid-acting glutamatergic agents, neuroactive steroids, hormonal therapies, and botanical preparations. An updated comparative synthesis of these treatments is therefore needed. To synthesize RCT evidence and compare the efficacy, response, remission,...

DOI: 10.1016/j.psychres.2026.117318 (opens in new tab) Full text (opens in new tab) Brexanolone Medication-based interventions Network meta-analysis Postpartum depression +2

Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study.

Psychiatry Research June 16, 2026 Filippo Mazzoni, Fabiola Raffone, Arianna De Ciechi et al.

Borderline personality disorder (BPD) often occurs alongside treatment-resistant depression (TRD), but the impact of BPD on real-world outcomes with intranasal esketamine is unclear. Consecutive TRD outpatients initiating intranasal esketamine treatment at four Italian centres between 1 September 2024 and 30 September 2025 were enrolled in the study (n = 90): 45 with comorbid BPD and 45 without...

The time Collapse-Entrapment model of depersonalization severity.

Psychiatry Research June 9, 2026 Sean P Madden, Mark R Serper

Depersonalization is a disruption in self-awareness marked by a sense of detachment from one's own thoughts, body, sensory experiences, actions, and emotions. While psychological distress and temporal disturbances are known correlates, the mechanisms through which these factors contribute to symptom severity remain poorly understood. The present study proposed and tested the Time...

DOI: 10.1016/j.psychres.2026.117272 (opens in new tab) Full text (opens in new tab) Depersonalization Derealization Entrapment Temporal blurring

Patterns of onset and progression of psychoses induced by psychoactive substance use.

Psychiatry Research June 1, 2026 Petru Ifteni, A. Miron, R.M. Necula et al.

INTRODUCTION Drug use in Europe has increased in recent years, including a marked rise in new psychoactive substances (NPS). Substance use disorders negatively affect physical and mental health. Psychotic disorders are highly prevalent among drug users. Establishing a link between illicit drug use and schizophrenia would help clarify the progression risk after substance-induced psychosis. AIMS...

Promoting self-compassion meditation with intranasal oxytocin in borderline personality disorder: a pilot study.

Psychiatry Research June 1, 2026 María Arqueros, Joaquim Soler, David Almenta et al.

BACKGROUND Borderline personality disorder (BPD) is characterized by emotion dysregulation, interpersonal difficulties, and high levels of self-criticism, which may hinder engagement with compassion-based therapeutic practices. Oxytocin has been proposed as a modulator of social-affective processes and may facilitate specific mechanisms involved in psychotherapy. METHODS In this pilot study, 18...

The influence of mindfulness therapy on NSSI and serum proBDNF in adolescents with depressive episode of depressive episode of bipolar disorder.

Psychiatry Research June 1, 2026 Peng Wang, Tong Wang, Yanling Wang et al.

There is a significant association between depressive episodes of bipolar disorder and non-suicidal self-injury (NSSI). Mindfulness-based cognitive therapy (MBCT) represents an evolution of cognitive behavioural therapy and serves as a comprehensive psychological intervention. Preliminary research suggests that MBCT may enhance cognitive flexibility and attentional adjustment in patients with...

Functional recovery trajectories in cannabis-induced first-episode psychosis: The role of dissociative symptoms in the discrepancy between symptomatic improvement and functional outcomes.

Psychiatry Research May 25, 2026 Valerio Ricci, Andrea Paggi, Giovanni Martinotti et al.

Functional recovery in cannabis-induced first-episode psychosis (FEP) remains incompletely understood. Dissociative symptoms, frequently associated with cannabis use, may represent a key but underexplored determinant of functional trajectories. This prospective cohort study followed 72 patients meeting DSM-5 criteria for cannabis-induced psychotic disorder over 24 months. Functional recovery...

DOI: 10.1016/j.psychres.2026.117240 (opens in new tab) Full text (opens in new tab) Cannabis-induced psychosis Depersonalization Dissociation First-episode psychosis +1

Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis.

Psychiatry Research May 12, 2026 Isis Lunsky, Gilmar Gutierrez, Xena Wang et al.

Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing promising results for PPD. This review searched the MEDLINE, CINAHL, PsycINFO, EMBASE, and Cochrane databases,...

DOI: 10.1016/j.psychres.2026.117221 (opens in new tab) Full text (opens in new tab) Esketamine Perinatal mental health Postpartum depression Psychopharmacology

Biological variations in ketamine sensitivity: insights from hyperlocomotion to psychotomimetic features in genetically diverse mouse strains.

Psychiatry Research April 1, 2026 Wen-Huei Siao, Tzong-Shi Wang, Liang-Chun Wang et al.

Ketamine, a non-competitive NMDA receptor antagonist, induces dissociative and psychotomimetic states and is widely used as an animal model for schizophrenia. However, strain-dependent variability in ketamine sensitivity is poorly understood, especially during adolescence, a developmental period marked by heightened vulnerability to NMDA receptor hypofunction. This study would compare...

DOI: 10.1016/j.psychres.2026.116995 (opens in new tab) Full text (opens in new tab) Animal model Genetic diversity Ketamine sensitivity Nmda receptor hypofunction +1

Single fixed-dose intranasal racemic ketamine treatment for the treatment of acute suicidality in a transdiagnostic patient population: Results of a pilot study.

Psychiatry Research March 1, 2026 Gijsbrecht H. J. Roelandt, Jurriaan F M Strous, Radboud M Marijnissen et al. 1 citation

Ketamine has been shown to decrease suicidality in patients with depression. However, little is known about tolerability and efficacy in heterogenous, acutely suicidal patients in emergency settings. This pilot study aimed to assess the feasibility, acceptability, and safety of generic intranasal racemic ketamine (75 mg) in the treatment of acute suicidality regardless of the underlying...

The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review

Psychiatry Research February 19, 2026 Trisha Menon, Andy Lu, Akhilan Arulmozhi et al.

Ketamine, esketamine, rTMS and ECT are associated with reductions in SI in persons with MDD, with the strongest evidence from randomized controlled trials supporting rapid, short-term effects, particularly for ketamine and esketamine. Further characterization and differentiation of the durability of antisuicidal effects of the aforementioned interventions requires investigation in large-scale,...

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

Psychiatry Research February 13, 2026 Sean P. Goldy, Nathan D. Sepeda, Samantha Hilbert et al. 1 citation

Psychedelics' characteristic acute subjective effects predict therapeutic benefits, such as decreases in depression and anxiety. Thus, optimizing treatment involves better understanding which factors shape subjective effects. Session facilitators, who support participants before, during, and after psychedelic administration sessions, form an important part of the setting of these experiences....

DOI: 10.1016/j.psychres.2026.117010 (opens in new tab) Psilocybin Clinical trial Multilevel model Sitting +10

A cost-utility analysis of mindfulness-based cognitive therapy versus cognitive behavioral therapy for major depressive disorder relapse prevention in primary care.

Psychiatry Research February 4, 2026 Waseem Abu-Ashour, Rick Audas, John-Michael Gamble et al.

Background: Major depressive disorder (MDD) is a chronic condition with high relapse rates affecting patients and health systems. Cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) are strategies for relapse prevention, but their comparative long-term cost-effectiveness remains unclear. Methods: We developed a cohort-based Markov model with three health states,...

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry Research February 2, 2026 Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al. 1 citation

Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...

Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review.

Psychiatry Research February 1, 2026 Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.

BACKGROUND Novel psychoactive substances (NPS) represent an evolving public health threat, yet evidence on their acute and long-term psychiatric consequences remains limited. OBJECTIVE To systematically review psychiatric and neurological consequences of NPS use across the full clinical spectrum, with primary focus on synthetic cannabinoids and related compounds, and to characterize...

Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)

Psychiatry Research December 29, 2025 Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain et al. 1 citation

Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary...

Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression.

Psychiatry Research December 1, 2025 Ahmed Z Elmaadawi, Imane Naha, Shruti Prabhudesai et al. 2 citations

Treatment-resistant depression (TRD) poses significant clinical challenges, often necessitating alternative treatments such as intravenous (IV) ketamine or intranasal esketamine. This study compared the effectiveness of these modalities and examined predictors of treatment response, including comorbidity profile, prior antidepressant failures, age, and gender. A retrospective chart review was...

Efficacy of esketamine after cesarean section for women with symptoms of prenatal depression: A randomized controlled trial.

Psychiatry Research November 16, 2025 Xue-Song, Ying-Yan Xu, Hua-Ping Xiong et al. 2 citations

Postpartum depression (PPD) is a major global health issue. Although esketamine shows promise for PPD, its preventive effect in cesarean patients with prenatal depression remains unclear. The aim of this trial was to evaluate the effect of perioperative esketamine treatment on PPD incidence in this high-risk population. This dual-center, double-blind, randomized, placebo-controlled trial...

DOI: 10.1016/j.psychres.2025.116849 (opens in new tab) Full text (opens in new tab) Esketamine Cesarean section High-risk population Postpartum depression prevention

A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings.

Psychiatry Research August 20, 2025 L. Mcinnes, Robert M. Berman, Matthew J Worley et al.

OBJECTIVE The study evaluated the effectiveness of Ketamine Intravenous Therapy (KIT) in reducing post-traumatic stress disorder (PTSD) and depression symptoms, using electronic health record data from outpatient psychiatric patients with PTSD. METHOD We analyzed data from 8,136 patients diagnosed with PTSD, 87 % (N = 7,070) of whom also had comorbid depression. Symptom severity was measured...